For the Inventor, By the Inventor

Enter assignee name

Durham, NC, United States of America

Precision Biosciences, Inc.

USPTO Granted Patents = 54

% Expired Patents = 1.9

EPO Patents = 43

Trademarks = 4

Forward Citations = 273

Loading Chart...

Loading Chart...

28 inventors (with patents filed for the assignee):

James Jefferson Smith (45 out of 65 patents)

Derek Jantz (40 out of 58 patents)

Victor Bartsevich (20 out of 20 patents)

4. Michael G Nicholson (18 out of 19 patents)

5. Daniel T MacLeod (14 out of 14 patents)

6. Jeyaraj Antony (12 out of 12 patents)

7. Janel Lape (10 out of 10 patents)

8. Aaron Martin (8 out of 8 patents)

9. Clayton Beard (5 out of 5 patents)

10. Jon E Chatterton (5 out of 5 patents)

11. John K Morris (5 out of 36 patents)

12. Hui Li (4 out of 4 patents)

13. Gary Owens (4 out of 4 patents)

14. Michelle Brenda Pires (3 out of 3 patents)

15. Caitlin Turner (3 out of 3 patents)

Core Competencies:

Genetically-Modified T Cells

Engineered Meganucleases

Hepatitis B Virus

Dystrophin Gene

Human T Cell Receptor

MicroRNA-adapted shRNA

Co-stimulatory Domains

Retinitis Pigmentosa

Nucleic Acid Molecules

Self-limiting Viral Vectors

Recognition Sequences

Mammalian Cell Lines

54 patents: Sort by Forward Citations

1. 12697400 - GENE EDITING METHODS FOR TREATING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY (2026-08-04),

2. 12668818 - MUSCLE-SPECIFIC EXPRESSION CASSETTES (2026-06-30),

3. 12655407 - ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME (2026-06-16),

4. 12644135 - POLYPEPTIDE LINKERS FOR USE IN ENGINEERED MEGANUCLEASES (2026-06-02),

5. 12595470 - ENGINEERED NUCLEASES THAT TARGET HUMAN AND CANINE FACTOR VIII GENES AS A TREATMENT FOR HEMOPHILIA A (2026-04-07),

6. 12595469 - TREATMENT OF RETINITIS PIGMENTOSA USING IMPROVED ENGINEERED MEGANUCLEASES (2026-04-07),

7. 12448613 - Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene (2025-10-21),

8. 12410418 - Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome (2025-09-09),

9. 12351839 - Rationally-designed single-chain meganucleases with non-palindromic recognition sequences (2025-07-08),

10. 12006522 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-06-11),

11. 11993793 - Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene (2024-05-28),

12. 11866747 - Engineered meganucleases that target human mitochondrial genomes (2024-01-09),

13. 11851680 - Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) (2023-12-26),

14. 11788077 - Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome (2023-10-17),

15. 11786554 - Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene (2023-10-17),

Precision BioSciences, Inc. is a biotechnology company that develops gene editing and cell therapy technologies. Their innovative platform, ARCUS, enables the precise modification of genes in living cells. By harnessing the power of ARCUS, Precision BioSciences aims to address a wide range of genetic diseases and advance the development of new therapies. The company is committed to providing safe and effective solutions for patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Precision Biosciences, Inc.

54 Patents

#20 in Durham, NC

#157 in North Carolina

#6,542 in US

#13,083 in the World

Durham, NC, United States of America

Precision Biosciences, Inc.

Forward Citations = 273

28 inventors:

James Jefferson Smith (45 out of 65 patents)

Derek Jantz (40 out of 58 patents)

Victor Bartsevich (20 out of 20 patents)

4. Michael G Nicholson (18 out of 19 patents)

5. Daniel T MacLeod (14 out of 14 patents)

Please report any incorrect information to [email protected]

Loading…